XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

The following tables set forth our segment information for the three and nine months ended September 30, 2024 and 2023, respectively (in thousands):

		Three Months Ended September 30, 2024
		MRD				Immune Medicine				Unallocated Corporate				Total
Revenue		$	37,470			$	8,965			$	—			$	46,435
Operating expenses			52,538				20,689				5,840				79,067
Adjusted EBITDA(1)			(6,120	)			(5,212	)			(2,968	)			(14,300	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss		$	(15,068	)		$	(11,724	)		$	(5,305	)		$	(32,097	)
Net loss attributable to noncontrolling interest			—				—				26				26
Net loss attributable to Adaptive Biotechnologies Corporation			(15,068	)			(11,724	)			(5,279	)			(32,071	)
Interest and other income, net			—				—				(3,474	)			(3,474	)
Interest expense(2)			—				—				2,939				2,939
Depreciation and amortization expense			2,428				1,728				435				4,591
Restructuring expense(3)			167				26				—				193
Share-based compensation expense(4)			6,353				4,758				2,411				13,522
Adjusted EBITDA(1)		$	(6,120	)		$	(5,212	)		$	(2,968	)		$	(14,300	)

		Three Months Ended September 30, 2023
		MRD				Immune Medicine				Unallocated Corporate				Total
Revenue		$	24,668			$	13,251			$	—			$	37,919
Operating expenses			55,977				26,400				6,498				88,875
Adjusted EBITDA(1)			(21,616	)			(4,986	)			(3,229	)			(29,831	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss		$	(31,309	)		$	(13,148	)		$	(5,869	)		$	(50,326	)
Net loss attributable to noncontrolling interest			—				—				26				26
Net loss attributable to Adaptive Biotechnologies Corporation			(31,309	)			(13,148	)			(5,843	)			(50,300	)
Interest and other income, net			—				—				(4,282	)			(4,282	)
Interest expense(2)			—				—				3,652				3,652
Depreciation and amortization expense			2,489				2,546				728				5,763
Share-based compensation expense(4)			7,204				5,616				2,516				15,336
Adjusted EBITDA(1)		$	(21,616	)		$	(4,986	)		$	(3,229	)		$	(29,831	)

		Nine Months Ended September 30, 2024
		MRD				Immune Medicine				Unallocated Corporate				Total
Revenue		$	105,380			$	26,118			$	—			$	131,498
Operating expenses			170,785				70,663				18,762				260,210
Adjusted EBITDA(1)			(34,668	)			(19,172	)			(10,086	)			(63,926	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss		$	(65,405	)		$	(44,545	)		$	(15,928	)		$	(125,878	)
Net loss attributable to noncontrolling interest			—				—				78				78
Net loss attributable to Adaptive Biotechnologies Corporation			(65,405	)			(44,545	)			(15,850	)			(125,800	)
Interest and other income, net			—				—				(11,462	)			(11,462	)
Interest expense(2)			—				—				8,628				8,628
Depreciation and amortization expense			7,733				5,777				1,298				14,808
Impairment of long-lived assets(3)			2,819				4,386				—				7,205
Restructuring expense(3)			1,195				722				—				1,917
Share-based compensation expense(4)			18,990				14,488				7,300				40,778
Adjusted EBITDA(1)		$	(34,668	)		$	(19,172	)		$	(10,086	)		$	(63,926	)

		Nine Months Ended September 30, 2023
		MRD				Immune Medicine				Unallocated Corporate				Total
Revenue		$	71,977			$	52,515			$	—			$	124,492
Operating expenses			170,946				88,753				20,760				280,459
Adjusted EBITDA(1)			(71,081	)			(11,149	)			(9,518	)			(91,748	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss		$	(98,969	)		$	(36,236	)		$	(20,632	)		$	(155,837	)
Net loss attributable to noncontrolling interest			—				—				28				28
Net loss attributable to Adaptive Biotechnologies Corporation			(98,969	)			(36,236	)			(20,604	)			(155,809	)
Interest and other income, net			—				—				(10,918	)			(10,918	)
Interest expense(2)			—				—				10,788				10,788
Depreciation and amortization expense			6,812				7,907				2,120				16,839
Share-based compensation expense(4)			21,076				17,180				9,096				47,352
Adjusted EBITDA(1)		$	(71,081	)		$	(11,149	)		$	(9,518	)		$	(91,748	)

(1) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.

(2) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

(3) Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.

(4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration